Welcome to our dedicated page for NATIONAL HEALTHCARE SEC filings (Ticker: NHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NATIONAL HEALTHCARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NATIONAL HEALTHCARE's regulatory disclosures and financial reporting.
NATIONAL HEALTHCARE CORP reported that Senior VP & General Counsel Josh A. McCreary received a grant of stock options to purchase 14,000 shares of common stock on February 23, 2026, at an exercise price of $0.00 per share.
The options were granted under the 2020 Omnibus Equity Incentive Plan and will vest in three equal parts: one-third on February 23, 2027, one-third on February 23, 2028, and the final one-third on February 23, 2029. The grant is described as exempt from Section 16(b) under Rule 16b-3(d).
National Healthcare Corp senior executive receives stock option grant. Sr. VP Patient Services Vicki L. Dodson was granted options to purchase 14,000 shares of National Healthcare Corp common stock on February 23, 2026, at an exercise price of $0.00 per share under the 2020 Omnibus Equity Incentive Plan.
According to the grant’s terms, these stock options vest in three equal installments: one-third on February 23, 2027, one-third on February 23, 2028, and the final one-third on February 23, 2029. Following the grant, she directly holds multiple option positions and 10,289.5455 shares of common stock in her name.
National Healthcare Corp CEO and director Stephen Fowler Flatt received a grant of 20,000 options to purchase common stock on February 23, 2026 under the 2020 Omnibus Equity Incentive Plan. The options have a stated exercise price of $0.00 per share in the filing.
These stock options vest and become exercisable in three equal installments: one-third on February 23, 2027, one-third on February 23, 2028, and the final one-third on February 23, 2029. After this grant, Flatt directly holds 20,000 of these options, alongside separately reported existing option and common stock holdings.
National Healthcare Corp SVP and CFO Brian F. Kidd received a grant of 14,000 options to purchase common stock on February 23, 2026. The options were granted at an exercise price of $0.00 under the 2020 Omnibus Equity Incentive Plan and are exempt from Section 16(b) under Rule 16b-3(d).
The options vest ratably over three years, with one-third vesting on February 23, 2027, one-third on February 23, 2028, and the final one-third on February 23, 2029. As of this grant, Kidd also directly held other option positions and 23,717 shares of common stock.
FLATT BEN ANDERSON SR reported acquisition or exercise transactions in this Form 4 filing.
National Healthcare Corp senior vice president and CIO Ben Anderson Flatt Sr reported an equity award of stock options. On February 23, 2026, he received options to purchase 14,000 shares of common stock under the 2020 Omnibus Equity Incentive Plan.
These options vest in three equal installments: one‑third on February 23, 2027, one‑third on February 23, 2028, and the final one‑third on February 23, 2029. The award is structured as long‑term incentive compensation rather than an open‑market share purchase.
NATIONAL HEALTHCARE CORP reported that Sr. VP of Operations Timothy J. Shelly received a grant of stock options to purchase 14,000 shares of common stock on February 23, 2026. The options were granted at an exercise price reported as $0.0000 per share.
The options were issued under the company’s 2020 Omnibus Equity Incentive Plan and will vest ratably over three years. One-third will vest on February 23, 2027, another one-third on February 23, 2028, and the final one-third on February 23, 2029, after which they become exercisable.
National HealthCare Corporation expanded its Board of Directors from seven to nine members effective February 12, 2026, appointing Dr. David Gifford and Andrew Adams as independent directors. Gifford joins as a Class 2 Director, expected to stand for a three‑year term at the 2027 annual meeting. Adams joins as a Class 1 Director and will be nominated for a three‑year term at the 2026 annual meeting.
Dr. Gifford brings long experience in geriatrics, public health leadership and long‑term care policy, while Adams contributes prior NHC facility administration experience and current leadership of a multilocation financial services business. Gifford will serve on the Nominating and Corporate Governance Committee and Adams on the Compensation Committee, and both will receive NHC’s standard non‑employee director compensation and indemnification.
National HealthCare Corporation announced a regular quarterly cash dividend of $0.64 per common share. The dividend will be paid to shareholders of record on March 31, 2026, with payment scheduled for April 30, 2026, reinforcing its ongoing cash return to shareholders.
As of February 1, 2026, NHC affiliates operate 80 skilled nursing facilities with 10,329 beds, 26 assisted living communities with 1,413 units, and nine independent living communities with 777 units, along with behavioral health hospitals, homecare, hospice, pharmacy, and rehabilitation services.
National Healthcare Corp (NHC) director James Paul Abernathy reported an option exercise and related share withholding. On January 15, 2026, he exercised an option granted in 2022 for 7,500 shares of common stock at a price of $69.82 per share. The company withheld 3,732 shares at $139.01 per share to pay the exercise price, resulting in net additional shares held.
Following these transactions, Abernathy beneficially owns 40,162 shares of NHC common stock, held directly. The exercised options were granted under the company’s 2020 Omnibus Equity Incentive Plan and are noted as exempt from certain short-swing profit rules. He also continues to hold option grants from 2023, 2024 and 2025, each covering 7,500 shares of common stock.
National Healthcare Corp Senior VP & General Counsel reported an equity transaction involving company stock. On 1/1/2026, a total of 1,162 shares of restricted stock that were originally granted on 3/8/2023, 3/5/2024, and 3/5/2025 vested. To cover tax obligations from this vesting, the company withheld 496 shares, recorded as a disposition at a price of $137.9 per share under transaction code F.
After this tax withholding, the insider directly beneficially owns 9,942 shares of National Healthcare Corp common stock. The filing also lists outstanding stock options giving rights to purchase additional shares in the future, all held directly by the reporting person.